The clinical effects of immune checkpoint inhibitors combined with anti-angiogenic agents for advanced non-small cell lung cancer
Not Applicable
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000044937
- Lead Sponsor
- Osaka University
- Brief Summary
ICI and AA therapy had significantly higher ORR than either monotherapy. PFS and OS were favorable benefits in ICI and AA therapy; however, significant heterogeneity was identified in these analyses. According to the administration timing and sequence, ICI immediately after AA showed no PFS and OS benefits compared to ICI monotherapy, whereas favorable PFS and OS were demonstrated when AA was concomitantly administered with ICI or when AA was administered immediately after ICI.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2414
Inclusion Criteria
Not provided
Exclusion Criteria
Patients without data about survival or tumor response
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method